{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:48:29Z","timestamp":1794556109395,"version":"4.9.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jcyt.2025.04.068","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T02:43:52Z","timestamp":1744944232000},"page":"980-990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A new sort of cells for chimeric antigen receptor T-cell therapies\u2014isolating CD14\u2013CD127+ T cells for chimeric antigen receptor T-cell manufacture"],"prefix":"10.1016","volume":"27","author":[{"given":"Yan","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqing","family":"Qie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha E.","family":"Gadd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2075-7919","authenticated-orcid":false,"given":"Tanya","family":"Hundal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1177-5272","authenticated-orcid":false,"given":"Andrew D.","family":"Brim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0825-9351","authenticated-orcid":false,"given":"Isas K. Vazquez","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2025.04.068_bib0001","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","article-title":"Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes","volume":"3","author":"Korell","year":"2022","journal-title":"Med"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0002","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/cancers16010046","article-title":"Chimeric antigen receptor-T cell therapy for lymphoma: new settings and future directions","volume":"16","author":"Savelli","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.878209","article-title":"CAR-T cell performance: how to improve their persistence?","volume":"13","author":"L\u00f3pez-Cantillo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0004","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.3390\/cancers14163991","article-title":"Immunotherapy of neuroendocrine neoplasms: any role for the chimeric antigen receptor T cells?","volume":"14","author":"Fanciulli","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0005","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13045-024-01602-0","article-title":"Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China\u2019s responses to address secondary cancer risks of CAR-T therapy","volume":"17","author":"Tan","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1063454","article-title":"Analysis of causes for poor persistence of CAR-T cell therapy in vivo","volume":"14","author":"Kong","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0007","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0008","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0009","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0010","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/imcb.12254","article-title":"Chimeric antigen receptor T cell persistence and memory cell formation","volume":"97","author":"McLellan","year":"2019","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0011","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/cancers8030036","article-title":"Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy","volume":"8","author":"Golubovskaya","year":"2016","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0012","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1073\/pnas.0308054101","article-title":"Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets","volume":"101","author":"Huster","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0013","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/labmed\/lmw053","article-title":"CD127 expression in naive and memory T cells in HIV patients who have undergone long-term HAART","volume":"48","author":"Xu","year":"2017","journal-title":"Lab Med"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0014","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cyto.2009.12.001","article-title":"IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers","volume":"50","author":"Sasson","year":"2010","journal-title":"Cytokine"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0015","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1007\/s00262-023-03537-w","article-title":"Translational development of a novel BAFF-R CAR-T therapy targeting B-cell lymphoid malignancies","volume":"72","author":"Luo","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0016","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1002\/mco2.716","article-title":"Targeting chronic lymphocytic leukemia with B-cell activating factor receptor CAR T cells","volume":"5","author":"Qie","year":"2024","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0017","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/j.1537-2995.2006.01033.x","article-title":"A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers","volume":"46","author":"Dietz","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0018","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41375-021-01477-x","article-title":"CD19\/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia","volume":"36","author":"Wang","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0019","article-title":"Solid cancer-directed CAR T-cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1","volume":"32","author":"Luo","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0020","doi-asserted-by":"crossref","first-page":"eaaw9414","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Qin","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0021","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/eji.201343751","article-title":"The who\u2019s who of T-cell differentiation: human memory T-cell subsets","volume":"43","author":"Mahnke","year":"2013","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002555","article-title":"Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies","volume":"9","author":"Tantalo","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0023","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e318270dec7","article-title":"Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale","volume":"35","author":"Wang","year":"2012","journal-title":"J Immunother"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0024","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/cyto.b.21771","article-title":"L-selectin expression is influenced by phosphatase activity in chronic lymphocytic leukemia","volume":"96","author":"Debreceni","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0025","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","article-title":"Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy","volume":"32","author":"Hollyman","year":"2009","journal-title":"J Immunother"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0026","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jcyt.2016.04.003","article-title":"Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells","volume":"18","author":"Stroncek","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1244298","article-title":"Regulating the regulatory T cells as cell therapies in autoimmunity and cancer","volume":"10","author":"Hosseinalizadeh","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0028","doi-asserted-by":"crossref","first-page":"104216","DOI":"10.1016\/j.ebiom.2022.104216","article-title":"Obstacles for T-lymphocytes in the tumour microenvironment: therapeutic challenges, advances and opportunities beyond immune checkpoint","volume":"83","author":"Verma","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0029","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy","volume":"28","author":"Good","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0030","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7150\/jca.14549","article-title":"PD-L1 expression is associated with tumor FOXP3(+) regulatory T-cell infiltration of breast cancer and poor prognosis of patient","volume":"7","author":"Li","year":"2016","journal-title":"J Cancer"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0031","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0032","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.omtm.2021.10.006","article-title":"Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALL","volume":"23","author":"Deng","year":"2021","journal-title":"Mol Ther\u2014Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0033","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.beha.2010.02.001","article-title":"Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells","volume":"23","author":"Damle","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0034","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005644","article-title":"Activated B cells suppress T-cell function through metabolic competition","volume":"10","author":"Imahashi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0036","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0037","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev-pathmechdis-012418-013058","article-title":"Monocytes in the tumor microenvironment","volume":"16","author":"Ugel","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0038","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.omtm.2021.06.014","article-title":"Depletion of high-content CD14+cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing","volume":"22","author":"Wang","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0039","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2018.10.004","article-title":"Manufacture of chimeric antigen receptor T cells from mobilized cyropreserved peripheral blood stem cell units depends on monocyte depletion","volume":"25","author":"K\u00fcnkele","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0040","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.omtm.2021.02.002","article-title":"Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing","volume":"20","author":"Noaks","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0041","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1186\/s12967-022-03833-6","article-title":"A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count","volume":"20","author":"Wang","year":"2022","journal-title":"J Transl Med"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0042","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145763","article-title":"Freeze and thaw of CD4+CD25+Foxp3+ regulatory T cells results in loss of CD62L expression and a reduced capacity to protect against graft-versus-host disease","volume":"10","author":"Florek","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0044","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0301-472X(00)00615-9","article-title":"Decrease of L-selectin expression on human CD34+ cells on freeze-thawing and rapid recovery with short-term incubation","volume":"29","author":"Hattori","year":"2001","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0045","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/microorganisms12010230","article-title":"Natural killer cells and cytotoxic T cells: complementary partners against microorganisms and cancer","volume":"12","author":"Vojdani","year":"2024","journal-title":"Microorganisms"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0046","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002866","article-title":"NK cells enhance CAR-T cell antitumor efficacy by enhancing immune\/tumor cells cluster formation and improving CAR-T cell fitness","volume":"9","author":"Bachiller","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0047","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40164-024-00522-6","article-title":"CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison","volume":"13","author":"Egli","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0048","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.4049\/jimmunol.175.7.4686","article-title":"Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor \u03b1 and CD62L1","volume":"175","author":"Bachmann","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0049","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1158\/1078-0432.CCR-13-1037","article-title":"CD62L as a therapeutic target in chronic lymphocytic leukemia","volume":"19","author":"Burgess","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0050","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.4103\/mmj.mmj_587_17","article-title":"CD62L expression in patients with chronic lymphocytic leukemia","volume":"32","author":"Soliman","year":"2019","journal-title":"Menoufia Med J"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0051","doi-asserted-by":"crossref","first-page":"8732","DOI":"10.1073\/pnas.161126098","article-title":"IL-7 is critical for homeostatic proliferation and survival of na\u00efve T cells","volume":"98","author":"Tan","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0052","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1084\/jem.20030735","article-title":"Interleukin 7 regulates the survival and generation of memory CD4 cells","volume":"198","author":"Kondrack","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0053","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/ni1009","article-title":"Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells","volume":"4","author":"Kaech","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0054","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1183698","article-title":"CD62L as target receptor for specific gene delivery into less differentiated human T lymphocytes","volume":"14","author":"Kapitza","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0056","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008989","article-title":"rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors","volume":"12","author":"Li","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0057","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/intimm\/dxae015","article-title":"High CD62L expression predicts the generation of chimeric antigen receptor T cells with potent effector functions","volume":"36","author":"Kasuya","year":"2024","journal-title":"Int Immunol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0058","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1158\/2159-8290.CD-20-1677","article-title":"Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy","volume":"11","author":"Chen","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0059","doi-asserted-by":"crossref","first-page":"eabm1463","DOI":"10.1126\/scitranslmed.abm1463","article-title":"Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies","volume":"14","author":"Goodman","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0060","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/2326-6066.CIR-20-0253","article-title":"CD28 costimulatory domain-targeted mutations enhance chimeric antigen receptor T-cell function","volume":"9","author":"Boucher","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0061","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1172\/JCI133215","article-title":"Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability","volume":"130","author":"Guedan","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0062","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3389\/fimmu.2017.01956","article-title":"Differences in expansion potential of naive chimeric antigen receptor T cells from healthy donors and untreated chronic lymphocytic leukemia patients","volume":"8","author":"Hoffmann","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0063","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0064","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0065","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/13696998.2019.1582059","article-title":"CAR T-cells: costs, comparisons, and commentary","volume":"22","author":"Hay","year":"2019","journal-title":"J Med Econ"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0066","article-title":"High cost of chimeric antigen receptor T-cells: challenges and solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0067","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191912366","article-title":"Price and prejudice? The value of chimeric antigen receptor (CAR) T-cell therapy","volume":"19","author":"Choi","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0068","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","volume":"221","author":"Ceja","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fmmed.2024.1310002","article-title":"Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy","volume":"4","author":"Colina","year":"2024","journal-title":"Front Mol Med"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0070","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0071","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jcyt.2024.03.003","article-title":"CAR-T cell expansion platforms yield distinct T cell differentiation states","volume":"26","author":"Song","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0072","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1158\/2326-6066.CIR-21-0501","article-title":"Modified manufacturing process modulates CD19CAR T-cell engraftment fitness and leukemia-free survival in pediatric and young adult subjects","volume":"10","author":"Ceppi","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0073","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1354825","article-title":"Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR\/Cas9 gene editing technology","volume":"15","author":"Tao","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2025.04.068_bib0074","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009476","article-title":"BCMA-BBZ-OX40 CAR-T therapy using an instant manufacturing platform in multiple myeloma","volume":"12","author":"Wang","year":"2024","journal-title":"J Immunother Cancer"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925006887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925006887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:10:06Z","timestamp":1762546206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925006887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1465324925006887"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.04.068","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new sort of cells for chimeric antigen receptor T-cell therapies\u2014isolating CD14\u2013CD127+ T cells for chimeric antigen receptor T-cell manufacture","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.04.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}